The Brazil Country Report provides an overview of the country's healthcare landscape, highlighting a population of over 205 million, a GDP of $2.1 trillion, and a health expenditure of 9% of GDP. It details the pharmaceutical market, emphasizing the significant presence of major international pharmaceutical companies and the government's role in supporting drug development. The report also notes the challenges and opportunities in the Brazilian pharmaceutical sector, including the need for aggressive medical education and the potential for growth in patented products.

1. HEALTH
mccannhealth.com
LET’S GET CONNECTED

2. COUNTRY REPORT BRAZIL
Produced in association with
McCann Health - AMK Healthcare
COUNTRY REPORT
OVERVIEW EXECUTIVE SUMMARY
Population: 205,716,890*
Life expectancy: 70 years (men); 77 years (women)
GDP: $2.1trn
GDP per capita: $11,127
Percentage of GDP spent on health: 9
GNI per capita: $9,390
Capital: Brasilia
President: Dilma Rousseff
Health Minister: Alexandre Padilha
Language: Portuguese
Currency: Real (BRL). Exchange rate: US$1 = R$1.72341
(Source: World Bank, 2010-11), *est. July CIA
June 2012 47

3. COUNTRY REPORT BRAZIL
MACRO OPERATING ENVIRONMENT HEALTHCARE POLICY & EXPENDITURE
HEALTHCARE SERVICES
HEALTHCARE REFORM
PHARMACEUTICAL EXPENDITURE
BRL 36.85bn
BRL29.10bn BRL7.75bn
$16.55bn $4.41bn PRICING AND REIMBURSEMENT
21%
79%
Over the Prescription
counter
Sources: Adapted from Brazilian Pharmaceutical Industry Federation (Febrafarma),
Group of Executives of the Pharmaceutical Market (Grupemef), IMS Health, BMI
48 June 2012

4. COUNTRY REPORT BRAZIL
PHARMACEUTICAL MARKET
-
regional hub
erode growth of patented
DISEASE BURDEN
PHARMACEUTICAL MARKET FORECAST (2007-2021)
June 2012 49

5. COUNTRY REPORT BRAZIL
MARKETING RESEARCH & DEVELOPMENT
“Brazil’s central government
remains a primary sponsor of
research, seeking to enlarge the
country’s drug development and
medical research capacity”
TOP 15 PHARMACEUTICAL AND HEALTHCARE COMPANIES IN BRAZIL BY REVENUE (2010)
Headquarters 2008 sales ($m) 2009 sales ($m) 2010 sales ($m)
Pfizer US 666.1 1,932.2 2,160.7
Novartis Switzerland 1,115.5 1,603.7 1,949.7
Sanofi France 1,228.9 1,583.9 1,900.0
Roche Switzerland 734.8 1,174.2 1,884.3
Medley Brazil 243.1 918.8 1,607.7
AstraZeneca UK-Switzerland 584.4 899.5 1,088.9
EMS Sigma Brazil 445.0 727.2 903.6
Eurofarma Brazil 423.6 696.3 839.8
Aché Brazil 455.8 683.7 823.9
Merck Germany 332.3 501.7 576.9
Eli Lilly US 545.2 819.0 560.6
Tortuga Brazil - 391.9 522.8
Laboratório Cristália Brazil 254.9 347.1 396.6
Biolab Sanus Farmacéutica Brazil 211.1 313.2 380.9
Bristol-Myers Squibb US 253.1 365.3 333.4
Source: Melhores & Maiores, BMI
50 June 2012

6. COUNTRY REPORT BRAZIL
COUNTERFEITING
GENERICS
MEDICAL DEVICES
PHARMACEUTICAL MARKET BY SUB-SECTOR
$bn (2010)
In vitro
in vitro
HEALTHCARE COMMUNICATIONS
Generic OTC Patented
Source: Brazilian Pharmaceutical Industry Federation (Febrafarma), Group of
Executives of the Pharmaceutical Market (Grupemef), IMS Health, BMI
June 2012 51

7. COUNTRY REPORT BRAZIL
OUTLOOK
“If pharma companies want to
improve their return on investment,
they have to adopt an aggressive
medical education approach and new
communication technologies”
“The potential for more expensive
patented products remains high,
given the country’s underdeveloped
R&D sector and reliance on imports”
Written by AMK Healthcare Communications – McCann Health. Contacts:
JD Puentes (left), President & CEO, AMK Healthcare Communications
Latin America and John Cahill, CEO, McCann Health. Emails: jdpuentes@
amkhealthcare.com and John.Cahill@Mccann.com
For comprehensive reports on other countries,
go to www.pmlive.com/countryreports
52 June 2012